摘要
前言:阿尔茨海默病(AD)是老年痴呆症最常见的病因,其特点是认知和功能逐渐下降。目前的治疗方案包括胆碱酯酶抑制剂(Cheis)多奈哌齐(Cheis)、加兰他明(Galantamine)和里维斯丁(Rivastigmin),以及N-甲基-天冬氨酸受体拮抗剂美丹汀(Memantine)。治疗指南建议使用胆碱酯酶(ChEIS)作为一线治疗的标准。一些随机的临床研究已经证明了ChEIS对认知、整体功能、行为和日常生活活动的有所改善。然而,由于缺乏疗效和/或安全性、耐受性问题和对治疗的依从性差,患者可能无法获得持续的临床上的疗效。 方法:对发表在“Pubmed”和“Medline”上的文章进行文献检索,使用预先指定的搜索术语,根据文章的标题、摘要和全文对文章进行批判性评价。 结果与结论:本综述的结果表明,剂量滴定和ChEIS之间的切换有助于改善CHI治疗的反应,也可以解决ADI患者缺乏/失去疗效或安全性/耐受性等问题,但需要精心设计的研究才能提供有力的证据。
关键词: 阿尔茨海默病,转换,AD治疗,胆碱酯酶抑制剂,痴呆,粘附。
Current Alzheimer Research
Title:Strategies for Continued Successful Treatment in Patients with Alzheimer’s Disease: An Overview of Switching Between Pharmacological Agents
Volume: 15 Issue: 10
关键词: 阿尔茨海默病,转换,AD治疗,胆碱酯酶抑制剂,痴呆,粘附。
摘要: Introduction: Alzheimer’s disease (AD) is the most common cause of dementia, characterized by a progressive decline in cognition and function. Current treatment options for AD include the cholinesterase inhibitors (ChEIs) donepezil, galantamine, and rivastigmine, as well as the N-methyl-Daspartate receptor antagonist memantine. Treatment guidelines recommend the use of ChEIs as the standard of care first-line therapy. Several randomized clinical studies have demonstrated the benefits of ChEIs on cognition, global function, behavior and activities of daily living. However, patients may fail to achieve sustained clinical benefits from ChEIs due to lack/loss of efficacy and/or safety, tolerability issues, and poor adherence to the treatment. The purpose of this review is to explore the strategies for continued successful treatment in patients with AD.
Methods: Literature search was performed for articles published in PubMed and MEDLINE, using prespecified search terms. Articles were critically evaluated for inclusion based on their titles, abstracts, and full text of the publication.
Results and Conclusion: The findings of this review indicate that dose up-titration and switching between ChEIs may help to improve response to ChEI treatment and also address issues such as lack/loss of efficacy or safety/tolerability in patients with AD. However, well-designed studies are needed to provide robust evidence.
Export Options
About this article
Cite this article as:
Strategies for Continued Successful Treatment in Patients with Alzheimer’s Disease: An Overview of Switching Between Pharmacological Agents, Current Alzheimer Research 2018; 15 (10) . https://dx.doi.org/10.2174/1567205015666180613112040
DOI https://dx.doi.org/10.2174/1567205015666180613112040 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sleep-Wake Patterns and Cognition of Older Adults with Amnestic Mild Cognitive Impairment (aMCI): A Comparison with Cognitively Healthy Adults and Moderate Alzheimer’s Disease Patients
Current Alzheimer Research Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies
Current Alzheimer Research Secondary Prevention of Atherothrombotic Cerebrovascular Events
Current Vascular Pharmacology Non-Communicable Diseases and Adherence to Mediterranean Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Commentary (Complement-Initiated Neuroinflammation and Its Role in Early Stage Alzheimers Disease)
Current Alzheimer Research Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials
Current Pharmaceutical Design Metal Protein Attenuating Compounds (MPACs): An Emerging Approach for the Treatment of Neurodegenerative Disorders
Current Bioactive Compounds A Review of Premature Frailty in HIV-Infected Persons; Another Manifestation of HIV-Related Accelerated Aging
Current Aging Science Alpha<sub>1</sub>-Adrenergic Receptor Antagonists Use in Treatment and Prevention of Psychiatric Disorders: A Review
Current Psychopharmacology Patient Education and Telemedicine in COPD - Update 2015
Current Respiratory Medicine Reviews Diverse Functions and Mechanisms of Pericytes in Ischemic Stroke
Current Neuropharmacology Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Synaptic Fatigue is More Pronounced in the APP/PS1 Transgenic Mouse Model of Alzheimers Disease
Current Alzheimer Research Neuroprotective and Preventative Effects of Molecular Hydrogen
Current Pharmaceutical Design The Vascular Component of Alzheimer`s Disease
Current Neurovascular Research Mitochondrial Abnormalities in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease
Current Alzheimer Research Age-Related Sleep Disruption and Reduction in the Circadian Rhythm of Urine Output: Contribution to Nocturia?
Current Aging Science Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design Editorial (Hot Topic: Neuroprotection and Neuroregeneration in Ischemic Stroke: Emerging Treatment Strategies and Potential Molecular Targets)
Current Drug Targets